MedTrace Logo

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery

NCT07766109 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 434

Last updated 2026-08-14

No results posted yet for this study

Summary

SGLT-2 inhibitors are recommended treatments for managing heart failure patients. In cases of surgery, it is recommended to stop the treatment 3 days before surgery due to the risk of postoperative euglycemic diabetic ketoacidosis. However, several data suggest that it may be beneficial to maintain SGLT-2i treatment given the possibility of improving postoperative cardiovascular outcomes. Investigator team wish to conduct a randomized controlled trial to test the hypothesis that preoperative maintenance of SGLT-2i is superior to discontinuing them 3 days before surgery in improving postoperative cardiovascular outcomes.

Conditions

Interventions

DRUG

treatment discontinuation

stop the SGLT-2 inhibitors treatment (dapagliflozine or empagliflozine) 3 days before surgery

DRUG

treatment continuation

maintain SGLT-2i treatment (dapagliflozine or empagliflozine) until surgery morning included

DIAGNOSTIC_TEST

ketone levels

Measurement of capillary ketone levels

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • François LABASTE, MD_PH · University Hospital of Toulouse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2029-01-31
Completion
2029-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07766109 on ClinicalTrials.gov